- Oral presentation
- Open Access
Effect of conservative treatments on QoL according to the SRS-22
© Atanasio et al; licensee BioMed Central Ltd. 2009
- Published: 15 January 2009
- Public Health
- Negative Impact
- Conservative Treatment
- Treated Patient
- Statistical Change
The SRS-22 has been developed to monitor QoL in scoliosis. Only a few studies have evaluated its effects on therapies. Consequently, doubts exist on its utility in conservative treatment.
To evaluate if SRS-22 is able to detect changes in patients treated conservatively.
Pre-post and cross-sectional study.
One hundred and thirty two consecutive AIS patients at their first evaluation, age 12.8 ± 2.7, divided into 5 groups according to treatment: 30 brace for 18 hours/day, 7 for 21 h/d, 33 for 23 h/d, 48 exercises and 14 observed (controls).
All patients compiled SRS-22 before the first and at the 6 months follow-up evaluations. Statistical analysis required ANOVA and Kruskall-Wallis tests.
Controls did not show changes with time, while all treated patients had increase of satisfaction with treatment. Aesthetic improvement was perceived by patients treated with exercises, while brace treated patients did show a psychological negative impact: these statistical changes were not clinically significant (0.2–0.3 points out of 5), excluding satisfaction (1.15–1.8). Between the groups, the 23 h/d showed worst start but best results in functioning, aesthetics, pain and satisfaction.
SRS-22 appears to detect changes in populations, but its clinical everyday use appears less reliable.
- Vasiliadis E, Grivas TB, Gkoltsiou K: Development and preliminary validation of Brace Questionnaire (BrQ): a new instrument for measuring quality of life of brace treated scoliotics. Scoliosis. 1: 7-10.1186/1748-7161-1-7. 2006 May 20;Google Scholar
- Vasiliadis E, Grivas TB: Quality of life after conservative treatment of adolescent idiopathic scoliosis. Stud Health Technol Inform. 2008, 135: 409-13.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd.